Bevicra 400 mg Injection 16 ml is a monoclonal antibody used to treat metastatic breast cancer, non-small cell lung cancer, kidney cancer, cervical cancer, epithelial ovarian, fallopian tube, or primary peritoneal cancer, cancer of colon and rectum. Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. Cancer can start in one region of the body and spread to other parts. This is referred to as metastasis.

Bevicra 400 mg Injection 16 ml contains 'Bevacizumab' that works against vascular endothelial growth factor (VEGF) which is found on the lining of lymph and blood vessels. VEGF causes blood vessels to grow within tumours which provide oxygen and nutrients to the tumour. Inhibition of vascular endothelial growth factor limits the flow of oxygen and nutrients to the tumour, causing it to shrink or cease developing. Thus, it helps treat cancers.

Bevicra 400 mg Injection 16 ml will be administered by a healthcare professional; do not self-administer. Based on your medical condition, your doctor will decide the dose and duration. In some cases, Bevicra 400 mg Injection 16 ml may cause loss of appetite, constipation, fever, nosebleeds, change in speech, and taste. The majority of these side effects do not require medical treatment and fade away with time. However, consult your doctor if the side effects persist or worsen

Avoid taking Bevicra 400 mg Injection 16 ml if you are pregnant. Use effective contraception during the treatment and for 6months after the last dose. Bevicra 400 mg Injection 16 ml may cause sleepiness and fainting, so avoid driving while on treatment with Bevicra 400 mg Injection 16 ml. Do not breastfeed during the treatment and for 6months after the last dose of Bevicra 400 mg Injection 16 ml. Keep your doctor informed about your health condition and all the medicines you take to rule out any side effects.

Bevicra 400 mg Injection 16 ml contains Bevacizumab, a monoclonal antibody used to treat metastatic breast cancer, non-small cell lung cancer, kidney cancer, cervical cancer, epithelial ovarian, fallopian tube, or primary peritoneal cancer, cancer of colon and rectum. Bevicra 400 mg Injection 16 ml works against a protein called vascular endothelial growth factor (VEGF). Vascular endothelial growth factor (VEGF) inhibition limits the flow of oxygen and nutrients to the tumour cells, causing them to shrink or cease developing. Thus, it helps treat cancer.

• Constipation
• Loss of appetite
• Fever
• Nose bleeds
• Change in speech
• Change in taste
• Voice changes/hoarseness
• Loss of body weight

Bevicra 400 mg Injection 16 ml should only be taken under medical supervision. While taking Bevicra 400 mg Injection 16 ml, the doctor will monitor your condition on a regular basis. If you have a history of allergic reactions to Bevicra 400 mg Injection 16 ml or other medications, inform your doctor before taking it. Avoid taking Bevicra 400 mg Injection 16 ml if you are pregnant. Use effective contraception during the treatment and for 6months after the last dose. Bevicra 400 mg Injection 16 ml may cause sleepiness and fainting, so avoid driving while on treatment with Bevicra 400 mg Injection 16 ml. Inform your doctor if you have/had high blood pressure, heart attack, stroke, bleeding problems, stomach/intestinal bleeding, perforation; if you had surgery in the past 28days/are due to have surgery. Do not breastfeed during the treatment and for 6months after the last dose of Bevicra 400 mg Injection 16 ml. While taking Bevicra 400 mg Injection 16 ml, please do not get any immunizations or vaccinations unless your doctor has approved it. Bevicra 400 mg Injection 16 ml may increase the risk of bleeding, so be cautious and consult your doctor if you notice any bleeding or bruising.

Drug-Drug Interactions: Bevicra 400 mg Injection 16 ml may have interaction with a drug used to treat renal and gastrointestinal cancer (sunitinib) and platinum or taxane-based therapies for lung or metastatic breast cancer. Inform your doctor if you have recently received, or are receiving, radiotherapy.

Drug-Food Interactions: Avoid the consumption of alcohol while taking Bevicra 400 mg Injection 16 ml.

Drug-Disease Interactions: Inform your doctor if you have/had infections, bleeding disorders, fistula formation (an abnormal connection between two body parts), GI perforation, hypertension, PRES (Posterior Reversible Encephalopathy Syndrome), proteinuria (abnormal quantities of protein in the urine), and thromboembolic disorders.

• SUNITINIB

• Meditating, reading novels, taking a nice bubble bath, or listening to calming music can all help you relax.
• Yoga can also aid in the improvement of both physical and mental health.
• Maintain a healthy weight by engaging in low-strain workouts on a regular basis and consuming nutritious foods.
• To maintain a healthy weight, eat a portion of nutritious food and exercise on a regular basis.
• Leafy greens, citrus fruits, fatty fish, berries, yoghurt, apples, peaches, cauliflower, cabbage, broccoli, beans, and herbs should all be part of your daily diet.
• Rest well and get a good night's sleep.
• Avoid smoking and consuming alcoholic beverages.
• Fast food, fried foods, processed meats, refined carbohydrates, and added sugars should be avoided.

• Your doctor may perform routine blood tests to evaluate your liver function, electrolyte levels, and blood cell count.
• Peripheral blood counts should be closely maintained during the treatment and, if necessary, until recovery.
• Wear protective clothing, sunglasses, and sunscreen to avoid unnecessary or prolonged exposure to sunlight and UV rays (such as tanning booths). Your skin may become sun-sensitive as a result of Bevicra 400 mg Injection 16 ml.
• Peripheral blood counts should be evaluated on a regular basis throughout Bevicra 400 mg Injection 16 ml treatment and until full recovery is achieved.

Cancer: It is a condition where cells in a specific part of the body grow and reproduce uncontrollably. The cancerous cells can invade and destroy surrounding healthy tissue, including organs. Cancer sometimes begins in one part of the body and spreads to other areas. It occurs due to mutations in genes that regulate cell growth. The mutations cause the cells to divide and multiply in an uncontrolled manner, leading to tumour formation. The most common cancer treatment methods are surgery, chemotherapy, radiotherapy, bone marrow (stem cell) transplantation, immunotherapy, and targeted drug therapy.